Company intelligence / Profile preview
Innovative Cellular Therapeutics
Rockville, Maryland, United Statesictbio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
GCC19CART has shown promising results in clinical trials for relapsed/refractory metastatic colorectal cancer (R/R mCRC). In a dose-escalation study in China, at dose level 2 (2 x 10^6 CAR-T/kg), the objective response rate (ORR) was 50%, with median overall survival (mOS) exceeding 26 months. In the U.S. Phase 1 study, at dose level 1 (1 x 10^6 CAR-T/kg), among four patients, the ORR was 50% with mOS of 17 months. At dose level 2 (12 x 10^6 CAR-T/kg), among five patients, the ORR was 80%, and the mOS has not yet been reached.[1][2][6]
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapiescellular immunotherapiesgene editing
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
Beyond the preview
Go deeper on Innovative Cellular Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innovative Cellular Therapeutics.